• JC-1 Mitochondrial Membrane Potential Assay Kit Guide

  2026-08-24

  Build a ratiometric mitochondrial membrane potential assay around JC-1 fluorescence, CCCP controls, and matched treatment conditions. This practical guide connects mitochondrial function analysis to apoptosis research, including a workflow for evaluating hypoxia-activated cancer therapies.

• LGK-974 PORCN Inhibitor: Wnt Research Workflows

  2026-08-24

  LGK-974 enables upstream, nanomolar interrogation of Wnt ligand secretion in cancer cell, co-culture, and xenograft workflows. This guide pairs practical PORCN inhibition with the CDK4/6–BET findings reported in pancreatic cancer research to improve model selection, pathway validation, and troubleshooting.

• BV6 IAP Antagonist: Apoptosis Workflow Guide

  2026-08-23

  BV6 is a Smac-mimetic IAP antagonist for mapping apoptosis, improving radiosensitization of non-small cell lung cancer, and testing combination cytotoxicity. This practical guide connects BV6 workflows with a mitochondrial-apoptosis study while separating directly supported findings from research-use recommendations.

• SAG for Astrocyte–Neuron Mechanism Studies

  2026-08-22

  SAG is a Smoothened receptor agonist that enables controlled Hedgehog pathway activation in glial and neuronal disease models. This article translates evidence from frataxin-deficient astrocytes into practical assay design, dose selection, and model-specific interpretation.

• Triazole ALDH2 Activators for Myocardial Ischemia

  2026-08-22

  The 2025 ACS Medicinal Chemistry Letters study developed triazole-based aldehyde dehydrogenase 2 activators with improved activity and water solubility, identifying Z17 as a particularly strong lead. In a mouse myocardial ischemia–reperfusion model, Z17 improved cardiac function and reduced biochemical and histological indicators of myocardial injury, while also illustrating the value and limitations of structure-guided activator design.

• SAG Workflows for Hedgehog Pathway Assays

  2026-08-21

  SAG provides a direct, controllable way to activate Smoothened in pathway assays, neurobiology models, and developmental studies. This guide connects practical dosing and assay controls with a recent screening study that shows how SAG can distinguish ligand-level Hedgehog inhibition from downstream Smoothened blockade.

• Spleen-Targeted mRNA Vaccine in HCC

  2026-08-20

  Lin et al. developed a spleen-targeted neoantigen mRNA vaccine that generated ISG15-positive CD8-positive T cells, promoted tertiary lymphoid structure formation, and produced strong antitumor activity in orthotopic hepatocellular carcinoma models. The study connects organ-selective delivery with a GZMA–F2R immune-cell interaction, offering a mechanistic framework for improving personalized RNA vaccine design.

• Hoechst 33342/PI Double Staining Kit Guide

  2026-08-20

  The Hoechst 33342/PI Double Staining Kit (SKU K2237) helps researchers distinguish normal, apoptotic, and necrotic cells by combining nuclear morphology with membrane-integrity staining. It is intended for controlled fluorescence-based research workflows, not clinical diagnosis, medical decisions, or direct interpretation without appropriate controls.

• Cytosolic DNA Drives TDP-43 Homeostasis Changes

  2026-08-19

  The reference study identifies cytosolic DNA accumulation as a trigger of reversible TDP-43 condensates, nuclear TDP-43 depletion, and increased production of a short TDP-43 isoform. Its combination of cell-based, genetic, and phase-separation experiments links DNA mislocalization with mechanisms relevant to ALS and other TDP-43 proteinopathies.

• GS-441524: Reliable Assay and PK Workflows

  2026-08-19

  This scenario-based guide explains how GS-441524, SKU B8461, can help laboratories control solubility, vehicle effects, storage, and parent–metabolite interpretation in viability and antiviral studies. It connects practical assay design with recent LC–MS/MS evidence relevant to GS-441524 pharmacokinetics and prodrug research.

• L-Phenylephrine: α1A Agonist Research Guide

  2026-08-18

  L-Phenylephrine is an adrenergic α1A receptor agonist used to study α1-adrenergic receptor signaling in cardiovascular, neural, and vascular models. Product data support receptor-selective binding, cardiomyocyte and neural progenitor assays, and research on nasal airway resistance, while mouse hypertension findings define important sex-aware experimental considerations.

• Rucaparib (AG-014699) for DNA Damage Assays

  2026-08-18

  Rucaparib (AG-014699) is a potent PARP1 inhibitor for mapping DNA repair vulnerabilities, radiosensitization, and genotype-dependent cancer phenotypes. This workflow pairs γ-H2AX and p53BP1 measurements with viability, transporter, and RNA Pol II-aware controls to distinguish persistent DNA damage from downstream apoptotic signaling.

• 3-Aminobenzamide (PARP-IN-1) Research Guide

  2026-08-17

  3-Aminobenzamide, also called PARP-IN-1, is a research inhibitor of poly (ADP-ribose) polymerase activity with a reported CHO-cell IC50 of approximately 50 nM. Its documented use cases include oxidative-stress, vascular, myocyte, diabetic nephropathy, and PARP-biology workflows, but assay-specific potency should not be generalized across models.

• Live-Dead Cell Staining Kit for Hypoxic GBM

  2026-08-17

  Explore how the Live-Dead Cell Staining Kit can resolve viability patterns in high-density, hypoxic glioblastoma models. This guide translates bioprinting findings into practical decisions for microscopy, flow cytometry, and drug-response assays.

• CDK4/6–BET Synergy in Pancreatic Cancer via Wnt

  2026-08-16

  Gu et al. show that combining the CDK4/6 inhibitor palbociclib with the BET inhibitor JQ1 suppresses pancreatic ductal adenocarcinoma more effectively than either agent alone while counteracting CDK4/6 inhibitor-associated EMT. The study links this effect to GSK3β-mediated Wnt/β-catenin regulation and provides a rationale for mechanism-guided combination therapy in PDAC.

8007 records 1/534 page Next 12345 下5页 Last page